BIOMAT Database Logo BIOMAT Database Logo

Sandimmun neoral, a new oral formulation of cyclosporin A with improved pharmacokinetic characteristics: safety and tolerability in renal transplant patients. 1994

S Taesch, and D Niese, and E A Mueller
Department of Clinical Research, Sandoz Pharma Ltd, Basle, Switzerland.

UI MeSH Term Description Entries
D003404 Creatinine Creatinine Sulfate Salt,Krebiozen,Salt, Creatinine Sulfate,Sulfate Salt, Creatinine
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D013997 Time Factors Elements of limited time intervals, contributing to particular results or situations. Time Series,Factor, Time,Time Factor
D016030 Kidney Transplantation The transference of a kidney from one human or animal to another. Grafting, Kidney,Renal Transplantation,Transplantation, Kidney,Transplantation, Renal,Kidney Grafting,Kidney Transplantations,Renal Transplantations,Transplantations, Kidney,Transplantations, Renal
D016572 Cyclosporine A cyclic undecapeptide from an extract of soil fungi. It is a powerful immunosupressant with a specific action on T-lymphocytes. It is used for the prophylaxis of graft rejection in organ and tissue transplantation. (From Martindale, The Extra Pharmacopoeia, 30th ed). Cyclosporin A,Ciclosporin,CsA-Neoral,CyA-NOF,Cyclosporin,Cyclosporine A,Neoral,OL 27-400,Sandimmun,Sandimmun Neoral,Sandimmune,CsA Neoral,CsANeoral,CyA NOF,OL 27 400,OL 27400

Related Publications

S Taesch, and D Niese, and E A Mueller
A study to assess the efficacy, tolerability, and safety of a new oral formulation of Sandimmun--Sandimmun Neoral--in stable renal transplant patients.
December 1995, Transplantation proceedings,
S Taesch, and D Niese, and E A Mueller
The efficacy, tolerability and safety of a new oral formulation of Sandimmun--Sandimmun Neoral in severe refractory atopic dermatitis.
November 1998, Journal of the European Academy of Dermatology and Venereology : JEADV,
S Taesch, and D Niese, and E A Mueller
Comparison of Neoral and Sandimmun cyclosporin A pharmacokinetic profiles in young renal transplant recipients.
June 1997, Pediatric nephrology (Berlin, Germany),
S Taesch, and D Niese, and E A Mueller
Safety and tolerability of CyA microemulsion formulation (Sandimmun Neoral) in stable renal transplant patients after 24 months of treatment. German Neoral Study Group.
August 1996, Transplantation proceedings,
S Taesch, and D Niese, and E A Mueller
Safety and tolerability of Sandimmun Neoral vs Sandimmun in de novo renal transplant patients after 24 months' treatment. German Neoral Study Group.
August 1996, Transplantation proceedings,
S Taesch, and D Niese, and E A Mueller
Safety, tolerability, and pharmacokinetics of Sandimmun Neoral: conversion study in stable renal transplant recipients.
June 1996, Transplantation proceedings,
S Taesch, and D Niese, and E A Mueller
Sandimmun neoral pharmacokinetics: impact of the new oral formulation.
February 1995, Transplantation proceedings,
S Taesch, and D Niese, and E A Mueller
The Swedish nationwide experience of converting transplant patients treated with Sandimmun to the new galenic formulation Sandimmun-neoral. The Swedish Sandimmun-Neoral Conversion Group.
January 1997, Transplantation proceedings,
S Taesch, and D Niese, and E A Mueller
The pharmacokinetics of Sandimmun Neoral: a new oral formulation of cyclosporine.
October 1994, Transplantation proceedings,
S Taesch, and D Niese, and E A Mueller
Pharmacokinetic behavior of cyclosporin A in rabbits by oral administration of lecithin vesicle and Sandimmun Neoral.
March 2001, International journal of pharmaceutics,
Copied contents to your clipboard!